MRK
MRNA
Well, that escalated fast
Moderna had one of those days that makes your portfolio feel like it just chugged three espressos. Shares exploded after the company and Merck said their personalized mRNA cancer vaccine succeeded in a Phase 3 melanoma trial.
For investors, this is the kind of result that can flip a whole story on its head. Moderna has spent years getting treated like the company that peaked during COVID and then got left at the party. This trial says: not so fast.
Not a cute little science fair project
This wasn’t a tiny lab study with hopeful vibes and a microscope. The INTerpath-001 trial enrolled 1,137 patients with completely resected stage IIB to IV melanoma, and the combination of Keytruda plus intismeran autogene beat Keytruda alone on:
- recurrence-free survival
- distant metastasis-free survival
No new safety issues showed up, which is usually the kind of detail that helps turn a promising headline into a real commercial story.
Why Wall Street is suddenly rethinking Moderna
The stock’s move was huge because the market wasn’t really set up for this. Moderna had been living in the shadow of its COVID windfall fading into a post-pandemic hangover, with investors mostly wondering what comes next.
Now they’ve got at least one very loud answer: mRNA might not just be a pandemic-era technology. If this cancer vaccine story keeps advancing, Moderna could start looking less like a one-hit vaccine wonder and more like a platform company with a real oncology future.
Big picture
This doesn’t make Moderna’s old problems disappear. But it does give the bulls something they badly needed: proof that the company’s science can work in a field way bigger than COVID. And in biotech, that kind of proof can be worth a lot more than a good quarter.